Early Response to Ketamine for Suicidal Crisis Reduces Suicidal Events at 3 Months

Martin Pastre, MD, Msc; Raphael Chancel, MD; Manon Malestroit, PhD; Philippe Courtet, MD, PhD; Emilie Olié, MD, PhD

J Clin Psychiatry 2025;86(3):25m15829

Abstract

Background: Intravenous (IV) ketamine has demonstrated rapid reduction of suicidal ideation (SI), but its impact on suicidal attempts remains unclear. This study investigates the effect of IV ketamine on SI at 7 days and suicidal events (suicide attempt or hospitalizations for SI) at 3 months in a real-world clinical setting.

Methods: We conducted an observational retrospective study including 100 adult French patients who received 1 or 2 IV ketamine infusions (0.5 mg/kg) within 1 week for a suicidal crisis between June 2022 and June 2024. Depressive symptoms (Montgomery-Asberg Depression Rating Scale) and SI severity (Columbia-Suicide Severity Rating Scale [C-SSRS]) were assessed at baseline and 7 days postinfusion. Suicidal events were collected from clinical records at 3 months.

Results: Ketamine significantly reduced depressive symptoms (β = −11; P < .001) and SI severity (β = −2.0; P < .001) at 7 days after controlling for age, sex, and number of infusions. A direct (β = −0.78; P < .001) and indirect effect (β = −0.29; P = .007) on SI through depression reduction was observed. Sixty-one percent of patients were SI responders (≥50% reduction in C-SSRS severity). SI responders at 7 days had 75% lower odds of experiencing suicidal events at 3 months (OR =0.25; P = .009).

Conclusion: This is the first study demonstrating that early SI response to IV ketamine is associated with a reduced risk of suicidal events at 3 months. These findings support ketamine’s unique antisuicidal properties beyond its antidepressant effects, highlighting its potential role in suicide prevention.

Trial Registration: ClinicalTrials.gov identifier: NCT06806475

J Clin Psychiatry 2025;86(3):25m15829

Author affiliations are listed at the end of this article.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you’re already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

References (35)

World Health Organization. Suicide Worldwide in 2019: Global Health Estimates. 1st ed. World Health Organization; 2021.
Franklin JC, Ribeiro JD, Fox KR, et al. Risk factors for suicidal thoughts and behaviors: a meta-analysis of 50 years of research. Psychol Bull. 2017;143(2):187–232. PubMed CrossRef
Lengvenyte A, Olié E, Strumila R, et al. Immediate and short-term efficacy of suicide-targeted interventions in suicidal individuals: a systematic review. World J Biol Psychiatry. 2021;22(9):670–685. PubMed CrossRef
Lengvenyte A, Giner L, Jardon V, et al. Assessment and management of individuals consulting for a suicidal crisis: a European Delphi method-based consensus guidelines. Span J Psychiatry Ment Health. 2023:S2950–2853(23)00113-8. doi: 10.1016/j.sjpmh.2023.12.001 PubMed CrossRef
Lengvenyte A, Strumila R, Olié E, et al. Ketamine and esketamine for crisis management in patients with depression: why, whom, and how? Eur Neuropsychopharmacol. 2022;57:88–104. PubMed CrossRef
Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Aust J Pharm. 2018;175(2):150–158. PubMed CrossRef
Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry. 2020;54(1):29–45. PubMed CrossRef
Bahji A, Vazquez GH, Zarate CA. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542–555. PubMed CrossRef
Xiong J, Lipsitz O, Chen-Li D, et al. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis. J Psychiatr Res. 2021;134:57–68. PubMed CrossRef
Li J, Ma L, Sun H, et al. Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2024. doi:10.1007/s00406-024-01920-x PubMed CrossRef
Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020;45(4):606–612. PubMed CrossRef
McIntyre RS, Rodrigues NB, Lee Y, et al. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian Rapid Treatment Center of Excellence. J Affect Disord. 2020;274:903–910. PubMed CrossRef
Feng W, Chen C, Zeng Y, et al. Efficacy of single and repeated ketamine administration for suicidal ideation in adults with psychiatric disorders: a meta analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111152. PubMed CrossRef
Pan Y, Gorenflo MP, Davis PB, et al. Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study. Transl Psychiatry. 2024;14(1):327. PubMed CrossRef
Chen CC, Zhou N, Hu N, et al. Acute effects of intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine on suicidal ideation: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2023;19:587–599. PubMed CrossRef
Zhan Y, Zhang B, Zhou Y, et al. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. J Affect Disord. 2019;251:205–212. PubMed CrossRef
Shen Z, Gao D, Lv X, et al. A meta-analysis of the effects of ketamine on suicidal ideation in depression patients. Transl Psychiatry. 2024;14(1):248–249. PubMed CrossRef
Williams NR, Heifets BD, Bentzley BS, et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry. 2019;24(12):1779–1786. PubMed CrossRef
Abbar M, Demattei C, El-Hage W, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ. 2022;376:e067194. PubMed CrossRef
Vande Voort JL, Ballard ED, Luckenbaugh DA, et al. Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder. J Clin Psychiatry. 2017;78(8):1068–1074. PubMed CrossRef
Yun JY, Kim YK. Neural correlates of treatment response to ketamine for treatment-resistant depression: a systematic review of MRI-based studies. Psychiatry Res. 2024;340:116092. PubMed CrossRef
Siegel AN, Di Vincenzo JD, Brietzke E, et al. Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: a systematic review. J Psychiatr Res. 2021;137:426–436. PubMed CrossRef
Chung DT, Ryan CJ, Hadzi-Pavlovic D, et al. Suicide rates after discharge from psychiatric facilities: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(7):694–702. PubMed CrossRef
American Psychiatric Publishing. Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TM, 5th ed. American Psychiatric Publishing, Inc; 2013.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389. PubMed CrossRef
Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. PubMed CrossRef
Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–1097. PubMed CrossRef
Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. PubMed CrossRef
Ballard ED, Yarrington JS, Farmer CA, et al. Characterizing the course of suicidal ideation response to ketamine. J Affect Disord. 2018;241:86–93. PubMed CrossRef
Turecki G, Brent DA. Suicide and suicidal behaviour. Lancet. 2016;387(10024):1227–1239. PubMed CrossRef
Ionescu DF, Luckenbaugh DA, Niciu MJ, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75(9):e932–e938. PubMed CrossRef
Pennybaker SJ, Luckenbaugh DA, Park LT, et al. Ketamine and psychosis history: antidepressant efficacy and psychotomimetic effects postinfusion. Biol Psychiatry. 2017;82(5):e35–e36. PubMed CrossRef
Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31(4):335–343. PubMed CrossRef
Sajid S, Galfalvy HC, Keilp JG, et al. Acute dissociation and ketamine’s antidepressant and anti-suicidal ideation effects in a midazolam-controlled trial. Int J Neuropsychopharmacol. 2024;27(4):pyae017. PubMed CrossRef